Cargando…

Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis

BACKGROUND: The optimal first-line immune checkpoint inhibitor (ICI) treatment strategy for metastatic or early triple-negative breast cancer (TNBC) has not yet been determined as a result of various randomized controlled trials (RCTs). The purpose of this study was to compare the efficacy and safet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Xueyan, Chen, Xiaoyu, Li, Huijuan, Li, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204114/ https://www.ncbi.nlm.nih.gov/pubmed/37229447 http://dx.doi.org/10.3389/fendo.2023.1137464

Ejemplares similares

Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
por: Heeke, Arielle L., et al.
Publicado: (2021)

Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors
por: Mesti, Tanja, et al.
Publicado: (2023)

Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis
por: Li, Yan, et al.
Publicado: (2023)

Endocrine side effects of immune checkpoint inhibitors
por: Cardona, Zulma, et al.
Publicado: (2023)

Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer
por: Simmons, Christine E., et al.
Publicado: (2020)

Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis
por: Xin, Yuanfang, et al.
Publicado: (2021)

Coexistence of Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes and Pancreatitis
por: Zhang, Amy L., et al.
Publicado: (2021)

Thyroid-related adverse events induced by immune checkpoint inhibitors
por: Chera, Alexandra, et al.
Publicado: (2022)

The Degree of Programmed Death-Ligand 1 (PD-L1) Positivity as a Determinant of Outcomes in Metastatic Triple-Negative Breast Cancer Treated With First-Line Immune Checkpoint Inhibitors
por: Di Spazio, Lorenzo, et al.
Publicado: (2022)

PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis
por: Yu, Yinan, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer?
por: Di Molfetta, Sergio, et al.
Publicado: (2021)

Editorial: Immune checkpoint inhibitors in cancer: balancing the benefits with the side effects?
por: Gomes-Lima, Cristiane J., et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker
por: Qureshi, Sadaf, et al.
Publicado: (2022)

Early Detection of Immune-Mediated Hypophysitis With Use of Checkpoint Inhibitor Immunotherapy
por: Yossef, Kristena, et al.
Publicado: (2022)

Immune checkpoint inhibitor-induced hypothyroidism predicts treatment response in Japanese subjects
por: Iwamoto, Yuichiro, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management
por: Zhan, Ling, et al.
Publicado: (2021)

First-line immune checkpoint inhibitors for patients with metastatic urothelial carcinoma treated in routine clinical practice
por: Naito, Renato, et al.
Publicado: (2020)

A novel conditional survival nomogram for monitoring real-time prognosis of non-metastatic triple-negative breast cancer
por: Meng, Xiangdi, et al.
Publicado: (2023)

First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis
por: Lin, Chang-Ting, et al.
Publicado: (2022)

Metabolic and Nutritional Disorders Following the Administration of Immune Checkpoint Inhibitors: A Pharmacovigilance Study
por: Zhai, Yinghong, et al.
Publicado: (2022)

Grading Central Diabetes Insipidus Induced by Immune Checkpoint Inhibitors: A Challenging Task
por: Barnabei, Agnese, et al.
Publicado: (2022)

Editorial: Decoding checkpoint inhibitor-induced immune-related adverse events, volume II
por: Burnett, Deborah L., et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
por: Thomas, Remy, et al.
Publicado: (2021)

Immune checkpoint inhibitor– and phosphatidylinositol-3-kinase inhibitor–related diabetes induced by antineoplastic drugs: two case reports and a literature review
por: Gao, Yue, et al.
Publicado: (2023)

Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors
por: Vici, Patrizia, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review
por: Hong, A Ram, et al.
Publicado: (2020)

Real-world adherence to toxicity management guidelines for immune checkpoint inhibitor-induced diabetes mellitus
por: Shen, Min, et al.
Publicado: (2023)

Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors
por: Abdou, Yara, et al.
Publicado: (2022)

Addition of Capecitabine to Adjuvant Chemotherapy May be the Most Effective Strategy for Patients With Early-Stage Triple-Negative Breast Cancer: A Network Meta-Analysis of 9 Randomized Controlled Trials
por: Li, Zhiyang, et al.
Publicado: (2022)

Outcome of Patients With Metastatic Lung Neuroendocrine Tumors Submitted to First Line Monotherapy With Somatostatin Analogs
por: Lenotti, Elisa, et al.
Publicado: (2021)

Editorial: Decoding checkpoint inhibitor-induced endocrinopathies
por: Burnett, Deborah L., et al.
Publicado: (2022)

Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus
por: Hilder, Robin, et al.
Publicado: (2023)

Case Report: Significant Response to the Combination of Lenvatinib and Immune Checkpoint Inhibitor in a Patient With Heavily Pretreated Metastatic Triple Negative Breast Cancer
por: Lee, Jin Sun, et al.
Publicado: (2021)

Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer
por: Liang, Xueyan, et al.
Publicado: (2023)

Opioids and immune checkpoint inhibitors differentially regulate a common immune network in triple-negative breast cancer
por: Scarpa, Joseph R., et al.
Publicado: (2023)

Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer
por: Tan, Qiaorui, et al.
Publicado: (2022)

Immune Checkpoints Inhibitors and Chemotherapy as First-Line Treatment for Metastatic Urothelial Carcinoma: A Network Meta-Analysis of Randomized Phase III Clinical Trials
por: Chen, Hsiao-Ling, et al.
Publicado: (2021)

A bibliometric and visualized research on global trends of immune checkpoint inhibitors related complications in melanoma, 2011–2021
por: Zhang, Hongyi, et al.
Publicado: (2023)

The Emerging Regulation of VEGFR-2 in Triple-Negative Breast Cancer
por: Zhu, Xiaoxia, et al.
Publicado: (2015)

Dietary Fructose Consumption and Triple-Negative Breast Cancer Incidence
por: Strober, Jordan W., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ob8kkok5284d19i9fumqa3lm01